On September 26, 2018 Syros Pharmaceuticals (NASDAQ: SYRS), a leader in the development of medicines that control the expression of genes, reported that its Chief Executive Officer, Nancy Simonian, M.D., will present a corporate overview at the 2018 Cantor Global Healthcare Conference. Details are as follows (Press release, Syros Pharmaceuticals, SEP 26, 2018, View Source [SID1234529603]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2018 Cantor Global Healthcare Conference
Date: Wednesday, October 3
Presentation Time: 8:35 a.m. ET
Location: InterContinental New York Barclay 111 E 48th St, New York, NY

A live webcast of the presentation will be available on the Investors & Media section of the Syros website at www.syros.com. An archived replay will be available for approximately 30 days following the fireside chat.

On September 26, 2018 Apexian Pharmaceuticals’ Chief Scientific Officer, Dr. Mark Kelley, reported that it has been awarded $2.3 million by the National Cancer Institute (NCI) to research the effects of APX3330 on chemotherapy-induced peripheral neuropathy (CIPN) (Press release, Apexian Pharmaceuticals, SEP 26, 2018, View Source [SID1234529731]). CIPN affects many cancer patients and can cause severe pain, loss of feeling, balance problems, muscle weakness, and even paralysis or organ failure. The symptoms may continue years after treatment ends. Currently, there is no effective treatment for CIPN.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Kelley’s research will focus on augmenting a DNA repair mechanism called APE1 to prevent or reverse CIPN using APX3330, a key molecule being used to treat solid tumors as part of a phase 1 clinical trial by Apexian Pharmaceuticals.

"Previous research has demonstrated APX3330’s effectiveness in protecting neurons and enhancing tumor-killing effects by itself or in combination with anticancer therapeutics, this could offer a win-win for preventing or treating CIPN," said Dr. Kelley, Apexian’s Chief Scientific Officer and the Betty and Earl Herr Professor of Pediatric Oncology Research at the Indiana University Simon Cancer Center.

"We appreciate the National Cancer Institute’s support of Dr. Kelley’s research," said Steve Carchedi, CEO of Apexian Pharmaceuticals. "In addition to acting on deadly forms of cancer involving the colon, pancreas, bladder, and brain, APX3330’s promise as a treatment for CIPN, for which there is currently no treatment, is very exciting."

The grant Dr. Kelley received is part of the NCI’s "Provocative Questions Initiative," which supports research designed to solve specific problems and paradoxes in cancer care that have not received sufficient attention. The funding will be awarded over five years.

On September 26, 2018 Tarveda Therapeutics, Inc., a clinical stage biopharmaceutical company discovering and developing Pentarins as a new class of potent and selective medicines to treat a wide range of cancers, reported that Drew Fromkin, President and Chief Executive Officer, will present at the Cantor Fitzgerald 2018 Global Healthcare Conference, occurring October 1-3, 2018 in New York City (Press release, Tarveda Therapeutics, SEP 26, 2018, View Source [SID1234529604]). Tarveda presentation details:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Wednesday, October 3, 2018
Time: 8:00 AM Eastern Time
Location: Intercontinental New York Barclay Hotel, New York City, NY

About Pentarins
Tarveda is developing Pentarins, potent and selective miniature drug conjugates with high affinity for specific cell surface and intracellular targets. Pentarins are engineered to bind to their tumor cell targets and provide sustained release of their potent therapeutic payloads deep into solid tumor tissue. Comprised of a targeting ligand conjugated to a potent cancer cell killing agent through a tuned chemical linker, Pentarins are designed to overcome the deficits of both larger antibody drug conjugates and small molecules that limit their therapeutic effectiveness against solid tumors. Together, the components of Tarveda’s Pentarins have distinct, yet synergistic, anticancer attributes: the small size of Pentarins allows for rapid and deep penetration into the tumor tissue, the ligand’s targeting ability allows for specific binding and retention in tumor cells, and the chemical linker is tuned to optimize the release of the potent, cell killing payload inside the cancer cells for efficacy.

On September 26, 2018 Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies to degrade disease-causing proteins, reported the pricing of its initial public offering of 7,500,000 shares of its common stock at a public offering price of $16.00 per share, for aggregate gross proceeds of approximately $120 million, before deducting underwriting discounts and commissions and estimated offering expenses (Press release, Arvinas, SEP 26, 2018, View Source [SID1234531302]). In addition, Arvinas has granted the underwriters an option for a period of 30 days to purchase up to 1,125,000 additional shares of common stock at the public offering price, less underwriting discounts and commissions. All of the shares are being offered by Arvinas.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The common stock is expected to begin trading on the Nasdaq Global Select Market on September 27, 2018 under the symbol "ARVN." The offering is expected to close on October 1, 2018, subject to customary closing conditions.

Goldman Sachs & Co. LLC, Citigroup and Piper Jaffray & Co., are acting as joint book-running managers for the offering.

A registration statement relating to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on September 26, 2018. The offering is being made only by means of a prospectus forming part of the registration statement relating to these shares. Copies of the prospectus, when available, may be obtained by contacting: Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, telephone: 866-471-2526, facsimile: 212-902-9316 or by emailing [email protected]; Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by telephone at 800-831-9146; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at 800-747-3924 or by email at [email protected].

This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

On September 26, 2018 Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a biotechnology company discovering and developing innovative immuno-oncology protein therapeutics, reported that Aron Knickerbocker, Chief Executive Officer, will present at the Leerink Partners Roundtable Series: Rare Disease & Oncology, Oct. 3, 2018, at 10:30 am ET (Press release, Five Prime Therapeutics, SEP 26, 2018, View Source [SID1234529605]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be webcast and may be accessed at the "Events & Presentations" section of the Company’s website at View Source Five Prime will maintain an archived replay of the webcast on its website for 30 days after the conference.